Matrix metalloproteinase-1 and tissue inhibitor of metalloproteinases-1 levels in severely obese patients: What is the effect of weight loss?

Experimental and Clinical Endocrinology and Diabetes

Volumn 118, Issue 10, 2010, Pages 730-734

  Papazoglou, D ^a   Papatheodorou, K ^a   Papanas, N ^a   Papadopoulos, T ^a   Gioka, T ^b   Kabouromiti, G ^b   Kotsiou, S ^a   Maltezos, E ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

metabolic syndrome; metalloproteinases; obesity; weight loss

Indexed keywords

INTERSTITIAL COLLAGENASE; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ANTHROPOMETRY; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADULT; AGED; ANTI-OBESITY AGENTS; BODY MASS INDEX; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY, MORBID; PROTEIN PRECURSORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; WEIGHT LOSS;

EID: 78349300619     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0030-1249671     Document Type: Article

References (32)

1. Beaudeux JL, Giral P, Bruckert E, et al. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med 2004 42 121-131
2. Belo VA, Souza-Costa DC, Lana CM, et al. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents. Clin Biochem 2009 42 984-990
3. Boden G, Song W, Kresge K, et al. Effects of hyperinsulinemia on hepatic metalloproteinases and their tissue inhibitors. Am J Physiol Endocrinol Metab 2008 295 E692-E697
4. Chavey C, Mari B, Monthouel MN, et al. Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. J Biol Chem 2003 278 11888-11896
5. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Hypertension 2003 42 1206-1252
6. Crandall DL, Hausman GJ, Kral JG. A review of the microcirculation of adipose tissue: anatomic, metabolic, and angiogenic perspectives. Microcirculation 1997 4 211-232
7. Demeulemeester D, Scroyen I, Voros G, et al. Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in mice does not affect adipogenesis or adipose tissue development. Thromb Haemost 2006 95 1019-1024
8. Deulemeester D, Collen D, Lijnen HR. Effect of matrix metalloproteinase inhibition on adipose tissue development. Biochem Biophys Res Commun 2005 329 105-110
9. Gerin I, Louis GW, Zhang X, et al. Hyperphagia and obesity in female mice lacking tissue inhibitor of metalloproteinase-1. Endocrinology 2009 150 1697-1704
10. Glowinska-Olszewska B, Urban M. Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents. Metabolism 2007 56 799-805
11. González-Reimers E, Castellano-Higuera A, Alemán-Valls R, et al. Relation between Body Fat and Liver Fat Accumulation and Cytokine Pattern in Non-Alcoholic Patients with Chronic HCV Infection. Ann Nutr Metab 2009 55 351-357
12. Grundy SM, Cleeman JI, Daniels SR, et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive Summary. Circulation 2005 112 e285-e290
13. Harris AK, Hutchinson JR, Sachidanandam K, et al. Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis: role of endothelin-1. Diabetes 2005 54 2638-2644
14. Hayakawa T, Yamashita K, Tanzawa K, et al. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 1992 298 29-32
15. Kosmala W, Plaksej R, Przewlocka-Kosmala M, et al. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function. Int J Obes (Lond) 2008 32 763-771
16. Kralisch S, Bluher M, Tonjes A, et al. Tissue inhibitor of metalloproteinase-1 predicts adiposity in humans. Eur J Endocrinol 2007 156 257-261
17. Kralisch S, Klein J, Lossner U, et al. Proinflammatory adipocytokines induce TIMP-1 expression in 3T3-L1 adipocytes. FEBS Lett 2005 579 6417-6422
18. Laimer M, Kaser S, Kranebitter M, et al. Effect of pronounced weight loss on the nontraditional cardiovascular risk marker matrix metalloproteinase-9 in middle-aged morbidly obese women. Int J Obes (Lond) 2005 29 498-501
19. Lijnen HR, Demeulemeester D, Van Hoef B, et al. Deficiency of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) impairs nutritionally induced obesity in mice. Thrombosis and Haemostasis 2003 89 249-255
20. Lijnen HR, Maquoi E, Hansen LB, et al. Matrix metalloproteinase inhibition impairs adipose tissue development in mice. Arterioscler Thromb Vasc Biol 2002 22 374-379
21. Madsen EL, Bruun JM, Skogstrand K, et al. Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects. Metabolism 2009 58 946-953
22. Maquoi E, Munaut C, Colige A, et al. Modulation of adipose tissue expression of murine matrix metalloproteinases and their tissue inhibitors with obesity. Diabetes 2002 51 1093-1101
23. Maury E, Ehala-Aleksejev K, Guiot Y, et al. Adipokines oversecreted by omental adipose tissue in human obesity. Am J Physiol Endocrinol Metab 2007 293 E656-E665
24. Mu H, Ohashi R, Yan S, et al. Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc Res 2006 70 146-157
25. Nho YK, Ha E, Yu KI, et al. Matrix metalloproteinase-1 promoter is associated with body mass index in Korean population with aged greater or equal to 50 years. Clin Chim Acta 2008 396 14-17
26. OHara A, Lim FL, Mazzatti DJ, et al. Microarray analysis identifies matrix metalloproteinases (MMPs) as key genes whose expression is up-regulated in human adipocytes by macrophage-conditioned medium. Pflugers Arch 2009 458 1103-1114
27. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nature Rev Mol Cell Biol 2007 8 221-233
28. Pendás AM, Folgueras AR, Llano E, et al. Diet-induced obesity and reduced skin cancer susceptibility in matrix metalloproteinase 19-deficient mice. Mol Cell Biol 2004 24 5304-5313
29. Pi-Sunyer FX. The obesity epidemic: pathophysiology and consequences of obesity. Obes Res 2002 10 S97-S104
30. Portik-Dobos V, Anstadt MP, Hutchinson J, et al. Evidence for a matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes. Diabetes 2002 51 3063-3068
31. Scroyen I, Cosemans L, Lijnen HR. Effect of tissue inhibitor of matrix metalloproteinases-1 on in vitro and in vivo adipocyte differentiation. Thromb Res 2009 124 578-583
32. Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 2000 14 2123-2133